TORONTO, March 19, 2018 /CNW/ - HLS Therapeutics Inc.
(TSXV: HLS) today announced that it will release its fourth quarter
2017 financial results by press release on Thursday, March 29, 2018, prior to market open.
The Company will subsequently hold a conference call that same day,
Thursday, March 29, at 8:30 am Eastern Time hosted by Mr. Greg Gubitz, Chief Executive Officer, Mr.
Gilbert Godin, President and Chief
Operating Officer and Tim
Hendrickson, VP Finance and Administration. A question and
answer session will follow the corporate update.
Conference Call Details
DATE:
|
Thursday, March 29,
2018
|
TIME:
|
8:30 am ET
|
DIAL-IN
NUMBER:
|
(888) 231-8191 or
(647) 427-7450
|
TAPED
REPLAY:
|
(855) 859-2056 or
(416) 849-0833
|
REFERENCE
NUMBER:
|
2483038
|
A link to the live audio webcast of the conference call will
also be available on the events page of the investors section of
HLS Therapeutics' website at www.hlstherapeutics.com. Please
connect at least 15 minutes prior to the conference call to ensure
adequate time for any software download that may be required to
hear the webcast. An archived webcast will be available for one
year.
About HLS
HLS (TSXV: HLS) is a specialty pharmaceutical company focused on
the acquisition and commercialization of late-stage development,
commercial-stage promoted and established, branded pharmaceutical
products in the North American markets. HLS's focus is on products
targeting the central nervous system and cardiovascular therapeutic
areas. HLS's management team is comprised of seasoned
pharmaceutical executives with a strong track record of success in
these therapeutic areas and at managing products in each of these
lifecycle stages.
Neither the TSX Venture Exchange nor its regulation services
provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
SOURCE HLS Therapeutics Inc.